Edgewise CEO reports RSU vesting, tax sales and new options

Q: What equity awards did Edgewise Therapeutics (EWTX) CEO Kevin Koch receive?

Kevin Koch received 100,000 RSUs and 200,000 stock options on August 12, 2026. The RSUs vest annually starting August 12, 2027, while the options, with a $43.56 exercise price, vest monthly over four years beginning September 12, 2026.

Q: How many Edgewise Therapeutics (EWTX) shares did the CEO sell in this Form 4?

Kevin Koch reported sales totaling 17,971 shares of common stock. Footnotes state these “sell-to-cover” transactions were executed solely to fund statutory tax withholding on vesting RSUs and were not discretionary sales.

Q: What RSU vesting activity did Edgewise Therapeutics (EWTX) report for its CEO?

Previously granted RSUs vested into 17,969 and 21,875 Edgewise Therapeutics common shares on August 12, 2026. A portion of these vested shares was then sold in “sell-to-cover” transactions to satisfy tax withholding obligations.

Q: What are the terms of the new Edgewise Therapeutics (EWTX) stock options granted to the CEO?

Kevin Koch was granted stock options on 200,000 shares of common stock at a $43.56 exercise price. The options vest in equal monthly installments (1/48th each month) starting September 12, 2026, and expire on August 12, 2036.

Q: Are the Edgewise Therapeutics (EWTX) CEO’s stock sales under a trading plan?

The Form 4’s Rule 10b5-1 checkbox is not marked, and footnotes describe the sales as sell-to-cover for statutory tax withholding on RSU vesting, indicating they were for tax obligations rather than discretionary trading.

Edgewise Therapeutics, Inc. President and CEO Kevin Koch reported multiple equity transactions on August 12, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Edgewise Therapeutics, Inc. President and CEO Kevin Koch reported multiple equity transactions on August 12, 2026. Previously granted RSUs converted into 17,969 and 21,875 shares of common stock, with a total of 17,971 shares sold in “sell-to-cover” trades solely to satisfy statutory tax withholding obligations, not as discretionary sales. Koch also received new awards of 100,000 RSUs, vesting in four annual installments beginning August 12, 2027, and 200,000 stock options with a $43.56 exercise price, vesting monthly over four years starting September 12, 2026.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 9 txns

Insider KOCH KEVIN

Role President and CEO

Sold 17,971 shs ($785K)

Approx. gross sale proceeds $785K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units ^F5	17,969	$0.00	$0.00
Exercise	Restricted Stock Units ^F6	21,875	$0.00	$0.00
Grant/Award	Restricted Stock Units ^F7	100,000	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy) ^F8	200,000	$0.00	$0.00
Exercise	Common Stock	17,969	$0.00	$0.00
Exercise	Common Stock	21,875	$0.00	$0.00
Sale	Common Stock ^{F1, F2}	8,782	$43.6408	$383K
Sale	Common Stock ^{F1, F3}	8,276	$43.6582	$361K
Sale	Common Stock ^{F1, F4}	913	$44.33	$40K

Holdings After Transaction: Restricted Stock Units — 201,563 contracts (Direct); Stock Option (Right to Buy) — 200,000 contracts (Direct); Common Stock — 52,488 shares (Direct)

Footnotes (8)

F1. Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person
F2. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $ 43.26 to $44.10, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $44.27, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.33 to $44.33, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.
F6. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
F7. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.
F8. 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.

Key Figures

RSUs vested to common stock: 17,969 shares Additional RSUs vested: 21,875 shares Shares sold to cover taxes: 17,971 shares +3 more

6 metrics

RSUs vested to common stock 17,969 shares RSUs converting into common stock on August 12, 2026

Additional RSUs vested 21,875 shares RSUs converting into common stock on August 12, 2026

Shares sold to cover taxes 17,971 shares Sell-to-cover transactions for statutory tax withholding on RSU vesting

New RSU grant 100,000 units RSUs vesting in four annual installments beginning August 12, 2027

New stock options granted 200,000 shares Options on common stock granted August 12, 2026

Stock option exercise price $43.56 per share Exercise price for 200,000 stock options expiring August 12, 2036

Key Terms

Restricted Stock Units ("RSUs"), sell-to-cover, statutory tax withholding obligations, Stock Option (Right to Buy)

4 terms

Restricted Stock Units ("RSUs") financial

"Restricted Stock Units ("RSUs") granted to the reporting person"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

sell-to-cover financial

"obligations to be funded by a "sell-to-cover" transaction"

Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.

statutory tax withholding obligations financial

"shares sold to cover the statutory tax withholding obligations"

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Edgewise Therapeutics (EWTX) CEO Kevin Koch receive?

Kevin Koch received 100,000 RSUs and 200,000 stock options on August 12, 2026. The RSUs vest annually starting August 12, 2027, while the options, with a $43.56 exercise price, vest monthly over four years beginning September 12, 2026.

How many Edgewise Therapeutics (EWTX) shares did the CEO sell in this Form 4?

Kevin Koch reported sales totaling 17,971 shares of common stock. Footnotes state these “sell-to-cover” transactions were executed solely to fund statutory tax withholding on vesting RSUs and were not discretionary sales.

What RSU vesting activity did Edgewise Therapeutics (EWTX) report for its CEO?

Previously granted RSUs vested into 17,969 and 21,875 Edgewise Therapeutics common shares on August 12, 2026. A portion of these vested shares was then sold in “sell-to-cover” transactions to satisfy tax withholding obligations.

What are the terms of the new Edgewise Therapeutics (EWTX) stock options granted to the CEO?

Kevin Koch was granted stock options on 200,000 shares of common stock at a $43.56 exercise price. The options vest in equal monthly installments (1/48th each month) starting September 12, 2026, and expire on August 12, 2036.

Are the Edgewise Therapeutics (EWTX) CEO’s stock sales under a trading plan?

The Form 4’s Rule 10b5-1 checkbox is not marked, and footnotes describe the sales as sell-to-cover for statutory tax withholding on RSU vesting, indicating they were for tax obligations rather than discretionary trading.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 08/14/2026 - 04:52 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KOCH KEVIN

(Last)

(First)

(Middle)

C/O EDGEWISE THERAPEUTICS, INC.

1715 38TH STREET

(Street)

BOULDER

COLORADO

80301

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/12/2026		M		17,969	A	$0.00	48,584	D
Common Stock	08/12/2026		M		21,875	A	$0.00	70,459	D
Common Stock	08/12/2026		S		8,782⁽¹⁾	D	$43.6408⁽²⁾	61,677	D
Common Stock	08/12/2026		S		8,276⁽¹⁾	D	$43.6582⁽³⁾	53,401	D
Common Stock	08/12/2026		S		913⁽¹⁾	D	$44.33⁽⁴⁾	52,488	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0.00	08/12/2026		M			17,969	⁽⁵⁾	08/12/2034	Common Stock	17,969	$0.00	35,938	D
Restricted Stock Units	$0.00	08/12/2026		M			21,875	⁽⁶⁾	08/12/2035	Common Stock	21,875	$0.00	65,625	D
Restricted Stock Units	$0.00	08/12/2026		A		100,000		⁽⁷⁾	08/12/2036	Common Stock	100,000	$0.00	100,000	D
Stock Option (Right to Buy)	$43.56	08/12/2026		A		200,000		⁽⁸⁾	08/12/2036	Common Stock	200,000	$0.00	200,000	D

Explanation of Responses:

1. Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person

2. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $ 43.26 to $44.10, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $44.27, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.33 to $44.33, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.

6. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.

7. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.

8. 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.

Remarks:

	/s/John R. Moore Attorney-in-Fact for Kevin Koch	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR